VolitionRx’s (VNRX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX) in a report published on Monday,Benzinga reports. They currently have a $5.00 target price on the stock.

Separately, StockNews.com initiated coverage on VolitionRx in a report on Friday, March 28th. They set a “sell” rating for the company.

VolitionRx Price Performance

Shares of NYSE VNRX opened at $0.54 on Monday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.02. The firm has a 50-day simple moving average of $0.58 and a two-hundred day simple moving average of $0.63. The company has a market cap of $50.10 million, a P/E ratio of -1.50 and a beta of 1.09.

Insider Buying and Selling at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds bought 181,818 shares of the business’s stock in a transaction on Wednesday, March 26th. The shares were acquired at an average price of $0.55 per share, with a total value of $99,999.90. Following the transaction, the chief executive officer now owns 2,299,222 shares of the company’s stock, valued at approximately $1,264,572.10. This trade represents a 8.59 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 12.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On VolitionRx

Hedge funds have recently made changes to their positions in the stock. Lagoda Investment Management L.P. grew its stake in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the last quarter. Geode Capital Management LLC grew its position in shares of VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after buying an additional 95,900 shares during the last quarter. Northern Trust Corp raised its stake in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after acquiring an additional 28,579 shares in the last quarter. Millennium Management LLC purchased a new stake in VolitionRx during the fourth quarter valued at approximately $36,000. Finally, Two Sigma Securities LLC acquired a new stake in VolitionRx in the fourth quarter valued at approximately $29,000. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.